Monika Sarkar1, Norah Terrault2, Wesley Chan1, Marcelle I Cedars3, Heather G Huddleston3, Caroline C Duwaerts1, Dana Balitzer4, Ryan M Gill4. 1. Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, CA, USA. 2. Department of Medicine, Division of Gastroenterology and Hepatology, University of Southern California, Los Angeles, CA, USA. 3. Center for Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, UCSF, San Francisco, CA, USA. 4. Department of Pathology, UCSF, San Francisco, CA, USA.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) affects 10% of reproductive-aged women, and is marked by irregular menses and high androgens. PCOS is a known risk factor for imaging-confirmed steatosis, and we now aim to evaluate whether PCOS influences histologic severity of non-alcoholic fatty liver disease (NAFLD). METHODS: Retrospective study of women ages 18-45 years with biopsy-confirmed NAFLD between 2008 and 2019. Metabolic comorbidities were captured within 6 months of biopsy. Histologic features of non-alcoholic steatohepatitis (NASH) were independently evaluated by two pathologists blinded to PCOS status. RESULTS: Among 102 women meeting study criteria, 36% (n = 37) had PCOS; median age was 35 years; 27% were white, 6% black, 19% Asian and 47% reported Hispanic ethnicity. Women with PCOS had higher LDL (122 vs 102 mg/dL, P = .05) and body mass index(BMI) (38 vs 33 kg/cm2 , P < .01). NASH was present in 76% of women with PCOS vs 66% without PCOS (P = .3), and a higher proportion with PCOS had severe ballooning (32% vs 13%, P = .02), presence of any fibrosis (84% vs 66%, P = .06) and advanced fibrosis (16% vs 6%, P = .10). Adjusted for age and BMI, PCOS remained associated with severe hepatocyte ballooning (OR 3.4, 95% CI 1.1-10.6, P = .03) and advanced fibrosis (OR 7.1, 95% CI 1.3-39, P = .02). Among women with advanced fibrosis, median age was 5 years younger in those with as compared to those without PCOS (40 vs 45 years, P = .02). CONCLUSION: Polycystic ovary syndrome is independently associated with more severe NASH, including advanced fibrosis. Hepatologists should routinely inquire about PCOS in reproductive-aged women with NAFLD, and evaluate for more severe liver disease in this population.
BACKGROUND:Polycystic ovary syndrome (PCOS) affects 10% of reproductive-aged women, and is marked by irregular menses and high androgens. PCOS is a known risk factor for imaging-confirmed steatosis, and we now aim to evaluate whether PCOS influences histologic severity of non-alcoholic fatty liver disease (NAFLD). METHODS: Retrospective study of women ages 18-45 years with biopsy-confirmed NAFLD between 2008 and 2019. Metabolic comorbidities were captured within 6 months of biopsy. Histologic features of non-alcoholic steatohepatitis (NASH) were independently evaluated by two pathologists blinded to PCOS status. RESULTS: Among 102 women meeting study criteria, 36% (n = 37) had PCOS; median age was 35 years; 27% were white, 6% black, 19% Asian and 47% reported Hispanic ethnicity. Women with PCOS had higher LDL (122 vs 102 mg/dL, P = .05) and body mass index(BMI) (38 vs 33 kg/cm2 , P < .01). NASH was present in 76% of women with PCOS vs 66% without PCOS (P = .3), and a higher proportion with PCOS had severe ballooning (32% vs 13%, P = .02), presence of any fibrosis (84% vs 66%, P = .06) and advanced fibrosis (16% vs 6%, P = .10). Adjusted for age and BMI, PCOS remained associated with severe hepatocyte ballooning (OR 3.4, 95% CI 1.1-10.6, P = .03) and advanced fibrosis (OR 7.1, 95% CI 1.3-39, P = .02). Among women with advanced fibrosis, median age was 5 years younger in those with as compared to those without PCOS (40 vs 45 years, P = .02). CONCLUSION:Polycystic ovary syndrome is independently associated with more severe NASH, including advanced fibrosis. Hepatologists should routinely inquire about PCOS in reproductive-aged women with NAFLD, and evaluate for more severe liver disease in this population.
Authors: Monika Sarkar; Melissa Wellons; Marcelle I Cedars; Lisa VanWagner; Erica P Gunderson; Veeral Ajmera; Laura Torchen; David Siscovick; J Jeffrey Carr; James G Terry; Mary Rinella; Cora E Lewis; Norah Terrault Journal: Am J Gastroenterol Date: 2017-03-14 Impact factor: 10.864
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Maya Gambarin-Gelwan; Sanjiv V Kinkhabwala; Thomas D Schiano; Carol Bodian; Hsu-Chong Yeh; Walter Futterweit Journal: Clin Gastroenterol Hepatol Date: 2007-02-06 Impact factor: 11.382
Authors: Neil F Goodman; Rhoda H Cobin; Walter Futterweit; Jennifer S Glueck; Richard S Legro; Enrico Carmina Journal: Endocr Pract Date: 2015-12 Impact factor: 3.443
Authors: Balachandran Kumarendran; Michael W O'Reilly; Konstantinos N Manolopoulos; Konstantinos A Toulis; Krishna M Gokhale; Alice J Sitch; Chandrika N Wijeyaratne; Arri Coomarasamy; Wiebke Arlt; Krishnarajah Nirantharakumar Journal: PLoS Med Date: 2018-03-28 Impact factor: 11.069
Authors: Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott Journal: Endocr Rev Date: 2020-07-01 Impact factor: 19.871
Authors: ShanHu Gao; Fei Long; Zheng Jiang; Jun Shi; DongXue Ma; Yang Yang; Jin Bai; Ting-Li Han Journal: Front Physiol Date: 2022-09-20 Impact factor: 4.755